🏅 FDA Orphan Designation

Nulibry

fosdenopterin

Manufacturer: Origin Biosciences, Inc.

Indicated for:

Sulfite oxidase deficiency due to molybdenum cofactor deficiency type COrphan

FDA-Approved Indications (1)

Sulfite oxidase deficiency due to molybdenum cofactor deficiency type COrphan Designation

to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A

Indications & Usage

1 INDICATIONS AND USAGE NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. NULIBRY is cyclic pyranopterin monophosphate (cPMP) indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. ( 1 )

💙 Support Programs

View all →

Nulibry

Origin Biosciences, Inc.

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.